MA56001A - Formes de sel cristallin d'un inhibiteur de kinase - Google Patents
Formes de sel cristallin d'un inhibiteur de kinaseInfo
- Publication number
- MA56001A MA56001A MA056001A MA56001A MA56001A MA 56001 A MA56001 A MA 56001A MA 056001 A MA056001 A MA 056001A MA 56001 A MA56001 A MA 56001A MA 56001 A MA56001 A MA 56001A
- Authority
- MA
- Morocco
- Prior art keywords
- kinase inhibitor
- salt forms
- crystalline salt
- crystalline
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856404P | 2019-06-03 | 2019-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA56001A true MA56001A (fr) | 2022-04-06 |
Family
ID=69160360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA056001A MA56001A (fr) | 2019-06-03 | 2019-12-12 | Formes de sel cristallin d'un inhibiteur de kinase |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20230052703A1 (fr) |
| EP (1) | EP3976587B1 (fr) |
| JP (1) | JP7579281B2 (fr) |
| KR (1) | KR102826380B1 (fr) |
| CN (1) | CN113939503B (fr) |
| AU (1) | AU2019449809B2 (fr) |
| BR (1) | BR112021024300A2 (fr) |
| CA (1) | CA3139148A1 (fr) |
| CL (1) | CL2021003205A1 (fr) |
| CO (1) | CO2021017343A2 (fr) |
| CR (1) | CR20210616A (fr) |
| DO (1) | DOP2021000236A (fr) |
| ES (1) | ES3008963T3 (fr) |
| GE (2) | GEAP202415849A (fr) |
| IL (1) | IL288484A (fr) |
| MA (1) | MA56001A (fr) |
| MX (1) | MX2021014773A (fr) |
| PE (1) | PE20220962A1 (fr) |
| PH (1) | PH12021553020A1 (fr) |
| SG (1) | SG11202111978VA (fr) |
| WO (1) | WO2020247019A1 (fr) |
| ZA (1) | ZA202108034B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEAP202415420A (en) * | 2018-01-26 | 2024-12-25 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| EP4631505A3 (fr) * | 2018-12-13 | 2025-12-10 | Exelixis, Inc. | Formes cristallines et formes salines d'un inhibiteur de kinase |
| AR127561A1 (es) * | 2021-11-03 | 2024-02-07 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
| JP2025500436A (ja) | 2021-12-22 | 2025-01-09 | エグゼリクシス， インコーポレイテッド | キナーゼ阻害剤の結晶性形態及び塩形態 |
| CN116751161A (zh) * | 2023-06-28 | 2023-09-15 | 中国人民解放军军事科学院军事医学研究院 | 喹啉类化合物及其制备方法、药物组合物及医药用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2744997A1 (fr) * | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | Modulateurs de c-met et procede d'utilisation |
| US7314622B2 (en) | 2005-04-15 | 2008-01-01 | Neogenix Oncology, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| KR101538707B1 (ko) * | 2010-07-14 | 2015-07-22 | 베타 파머수티컬 컴퍼니 리미티드 | c-MET 티로신 키나제 억제제로서 유용한 신규 융합된 헤테로사이클릭 유도체 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US20180009758A1 (en) * | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| IL270780B2 (en) * | 2017-05-26 | 2025-04-01 | Exelixis Inc | Crystalline solid forms of salts of N–{4–[(7,6–dimethoxyquinolin–4–yl)oxy]phenyl}–N'–(4–fluorophenyl)cyclopropane–1,1–dicarboxamide, processes for preparation and methods of use |
| GEAP202415420A (en) * | 2018-01-26 | 2024-12-25 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| EP4631505A3 (fr) * | 2018-12-13 | 2025-12-10 | Exelixis, Inc. | Formes cristallines et formes salines d'un inhibiteur de kinase |
| CN109761899B (zh) * | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
-
2019
- 2019-12-12 SG SG11202111978VA patent/SG11202111978VA/en unknown
- 2019-12-12 US US17/616,124 patent/US20230052703A1/en active Pending
- 2019-12-12 GE GEAP202415849A patent/GEAP202415849A/en unknown
- 2019-12-12 AU AU2019449809A patent/AU2019449809B2/en active Active
- 2019-12-12 GE GEAP201915849A patent/GEP20247655B/en unknown
- 2019-12-12 MX MX2021014773A patent/MX2021014773A/es unknown
- 2019-12-12 CR CR20210616A patent/CR20210616A/es unknown
- 2019-12-12 PH PH1/2021/553020A patent/PH12021553020A1/en unknown
- 2019-12-12 PE PE2021002015A patent/PE20220962A1/es unknown
- 2019-12-12 JP JP2021571744A patent/JP7579281B2/ja active Active
- 2019-12-12 CA CA3139148A patent/CA3139148A1/fr active Pending
- 2019-12-12 MA MA056001A patent/MA56001A/fr unknown
- 2019-12-12 EP EP19836340.0A patent/EP3976587B1/fr active Active
- 2019-12-12 CN CN201980097028.2A patent/CN113939503B/zh active Active
- 2019-12-12 ES ES19836340T patent/ES3008963T3/es active Active
- 2019-12-12 BR BR112021024300A patent/BR112021024300A2/pt unknown
- 2019-12-12 WO PCT/US2019/065980 patent/WO2020247019A1/fr not_active Ceased
- 2019-12-12 KR KR1020217041796A patent/KR102826380B1/ko active Active
-
2021
- 2021-10-20 ZA ZA2021/08034A patent/ZA202108034B/en unknown
- 2021-11-17 DO DO2021000236A patent/DOP2021000236A/es unknown
- 2021-11-28 IL IL288484A patent/IL288484A/en unknown
- 2021-12-02 CL CL2021003205A patent/CL2021003205A1/es unknown
- 2021-12-16 CO CONC2021/0017343A patent/CO2021017343A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3976587B1 (fr) | 2024-12-04 |
| IL288484A (en) | 2022-01-01 |
| CO2021017343A2 (es) | 2022-01-17 |
| AU2019449809B2 (en) | 2026-02-05 |
| SG11202111978VA (en) | 2021-11-29 |
| BR112021024300A2 (pt) | 2022-01-11 |
| ES3008963T3 (en) | 2025-03-25 |
| PH12021553020A1 (en) | 2023-08-23 |
| AU2019449809A1 (en) | 2021-12-16 |
| EP3976587A1 (fr) | 2022-04-06 |
| WO2020247019A1 (fr) | 2020-12-10 |
| MX2021014773A (es) | 2022-01-18 |
| GEAP202415849A (en) | 2024-03-11 |
| KR20220016117A (ko) | 2022-02-08 |
| CR20210616A (es) | 2022-03-22 |
| JP7579281B2 (ja) | 2024-11-07 |
| US20230052703A1 (en) | 2023-02-16 |
| CN113939503B (zh) | 2024-05-07 |
| JP2022535072A (ja) | 2022-08-04 |
| PE20220962A1 (es) | 2022-06-10 |
| EP3976587C0 (fr) | 2024-12-04 |
| GEP20247655B (en) | 2024-08-26 |
| CA3139148A1 (fr) | 2020-12-10 |
| DOP2021000236A (es) | 2022-04-18 |
| KR102826380B1 (ko) | 2025-06-26 |
| CL2021003205A1 (es) | 2022-09-30 |
| CN113939503A (zh) | 2022-01-14 |
| ZA202108034B (en) | 2025-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3947361A4 (fr) | Sel et forme cristalline d'un inhibiteur de fak | |
| EP3924352A4 (fr) | Formes cristallines d'un inhibiteur rsk | |
| MA54458A (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
| MA53226A (fr) | Sel et formes cristallines d'omecamtiv mecarbil | |
| EP3870178A4 (fr) | Formes cristallines d'inhibiteurs de mnk | |
| MA54526A (fr) | NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta | |
| MA55614A (fr) | Formes cristallines d'inhibiteur de pyridazinone trpc | |
| EP3619208C0 (fr) | Formes cristallines d'un composé inhibiteur de jak | |
| EP3472168A4 (fr) | Formes cristallines d'un composé de triazolopyrimidine | |
| IL288484A (en) | Crystalline salt forms of a kinase inhibitor | |
| DK4055021T3 (da) | Heterocykliske rip1-inhiberende forbindelser | |
| EP3807279A4 (fr) | Sels pharmaceutiquement acceptables de sépiaptérine | |
| MA55801A (fr) | Formes solides d'un inhibiteur de glyt1 | |
| MA51082A (fr) | Un sel de sodium du n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazole-3-sulfonamide | |
| IL289929A (en) | Crystal forms of cd73 inhibitor | |
| EP3897660A4 (fr) | Nouvelles formes cristallines d'un composé de nrtti | |
| EP3873463A4 (fr) | Sels cristallins d'un inhibiteur de la kallicréine plasmatique | |
| EP3829551A4 (fr) | Sel de malonate d'épinéphrine cristallin | |
| MA54638A (fr) | Formes cristallines d'un stimulateur de sgc | |
| SG11202102110PA (en) | Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor | |
| EP4019496A4 (fr) | Sel et forme cristalline d'un composé ayant une activité agoniste vis-à-vis du récepteur s1p5 | |
| EP3996707A4 (fr) | Formes cristallines d'inhibiteurs de la kallicréine plasmatique | |
| EP3847175A4 (fr) | Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k) | |
| EP3896063A4 (fr) | Sel d'inhibiteur de syk et forme cristalline correspondante | |
| EP3849964A4 (fr) | Formes cristallines d'un composé de quinazole et ses sels de chlorhydrate |